An independent Data Safety Monitoring Board (DSMB) confirms EB103’s favorable safety profile with no treatment-related serious adverse events (SAEs) even in high-risk patients who are ineligible for ...
The phase 1/2 STARLIGHT-1 trial has dosed the first patient in the second cohort of the study evaluating EB103 in advanced B-cell non-Hodgkin’s lymphomas. The phase 1/2 STARLIGHT-1 trial has dosed the ...
The study has achieved a 100% complete response (CR) rate at Month 1 in all evaluable patients treated in the second dose cohort. All patients treated are considered high-risk group who are not ...
EMERYVILLE, Calif.--(BUSINESS WIRE)-- Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS® ...
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, including but not limited to those regarding the ...
On Thursday, Estrella Immunopharma Inc. (NASDAQ:ESLA) announced the activation of a second clinical site for its ongoing STARLIGHT-1 Phase I/II clinical trial. The trial is evaluating EB103, which is ...
EMERYVILLE, Calif.--(BUSINESS WIRE)--Estrella Immunopharma, Inc. (NASDAQ: ESLA) (“Estrella” or the “Company”), a clinical stage biopharmaceutical company developing CD19 and CD22-targeted ARTEMIS ® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results